Skip to main content
SpringerLink
Log in

Olanzapine in Schizophrenia and Affective Disorders

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moteshafi H, Zhornitsky S, Brunelle S, et al. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf 2012; 35(10): 819–36

    Article  PubMed  CAS  Google Scholar 

  2. Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 2007 Aug; 50: S64–70

    Article  PubMed  Google Scholar 

  3. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006 Jan; 67(1): 107–13

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part by a Josep Font Research Grant from the Hospital Clínic of Barcelona (to Juan Undurraga); the Instituto de Salud Carlos III through the Centro para la Investigación Biomédica en Red de Salud Mental (CIBERSAM) [to Juan Undurraga, Eduard Vieta and Francesc Colom]; a Miguel Servet postdoctoral contract (CP08/00140) and an FIS (PS09/01044) [Francesc Colom]; and the Generalitat de Catalunya to Bipolar Disorders Group (2009 SGR 1022) [Juan Undurraga, Eduard Vieta and Francesc Colom].

Professor Vieta is a consultant or grant recipient with Almirall, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Sanofi, Servier, Schering-Plough, Shire, Takeda and United Biosource Corporations. Dr Francesc Colom has served as advisory or speaker for the following companies: Adamed, AstraZeneca, Bristol-Myers, Eli-Lilly, GlaxoSmithKline, Lundbeck, MSD-Merck, Otsuka, Pfizer Inc., Sanofi-Aventis, Shire and Tecnifar. He has received copyright fees from Cambridge University Press, Solal Ed., Ars Médica, Giovani Fioriti Ed., Medipage, La Esfera de Los Libros, Morales i Torres Ed, Panamericana, Mayo Ed. and Columna. Dr Mauricio Tohen was an Eli Lilly employee and has received honoraria from or been a consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, Sepracor, Otsuka, Merck, Sunovion, Forest, Lundbeck and Wyeth. His spouse is a current employee and minor stockholder of Eli Lilly. Dr Juan Undurraga declares no conflicts of interest.

Author information

Authors and Affiliations

  1. Bipolar Disorders Program, Institute of Neuroscience, Hospital Clínic Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain

    Juan Undurraga, Eduard Vieta & Francesc Colom

  2. Division of Mood and Anxiety Disorders, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

    Mauricio Tohen

Authors
  1. Juan Undurraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduard Vieta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mauricio Tohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesc Colom
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Undurraga, J., Vieta, E., Tohen, M. et al. Olanzapine in Schizophrenia and Affective Disorders. Drug Saf 35, 1185–1186 (2012). https://doi.org/10.1007/BF03262005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262005

Keywords

Search

Navigation